Wire · opportunities
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
Arrowhead Pharmaceuticals will present pivotal Phase 3 clinical trial results for plozasiran, a treatment for severe hypertriglyceridemia, at the European Society of Cardiology Congress in Munich. The drug is already approved in multiple major markets and targets high triglyceride levels associated with acute pancreatitis and cardiovascular disease.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 24 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
Cardiovascular drug developers should note that plozasiran's positive Phase 3 data and existing multi-market approvals open new routes for treatment and competitive positioning in severe hypertriglyceridemia care.
◆ Coverage
2 sources · first reported 24 Aug 2026 · latest 31 Aug 2026
◆ Related on Wire
◆ Topics